Health Care · Orthopedic, Prosthetic & Surgical Appliances & Supplies · NYSE · CIK 1099800 · FYE Dec 31 · Prices AT CLOSE 2026-08-20 (USD) Last $89.83 · Day −2.65% · Mkt cap $53.2B · P/E (FY) 50.4× · 1Y +10.4% · Off 52W high −6.7% · Vol (1Y) 24.9% Price2023-08-21 → 2026-08-20 EW close: $76.3 on 2023-08-21 to $89.8 on 2026-08-20. Split-adj closes · 240 of 6,637 · price returnⓘ At a glance | Short interest1.7% of sh out | | Days to cover1.8d | | 13F net flow (QoQ)+0.58% | | Top-10 13F concentration48.4% | | Next report (est.)2026-10-23 |
SI 2026-07-31 · 13F 2026-Q1ⓘ Key fundamentalsFY 2025 | P/E (FY)50.4× | | Sales (TTM)$6.51B | | Earnings (TTM)$1.00B | | ROE10.6% | | Net margin17.7% | | ROIC15.7% | | Debt / equity0.06× | | Total debt / EBITDA0.42× | | EPS growth 3Y−9.1% | | Sales growth 3Y10.8% |
FY ratios · TTM sales/earnings (USD)ⓘ Trailing returns | YTD+5.4% | | 1Y+10.4% | | 3Y+17.7% | | 5Y−24.5% | | 10Y+130.4% | | Since incept. (ann.)+17.2% |
Total return · from 2000-03-27ⓘ Risk | Ann. volatility (1Y)24.9% | | Ann. volatility (3Y)31.7% | | Sharpe (1Y)0.65 | | Sharpe (3Y)0.34 | | Max drawdown (1Y)−13.2% | | Max drawdown (3Y)−37.5% | | Beta (3Y vs SPY)0.84 |
Daily returns, ann.ⓘ Top institutional holders13F 2026-Q1 | Manager | Shares | Value | % sh out | QoQ |
|---|
| BlackRock, Inc. | 52.6M | $4.2B | 9.05% | +0.2% | | VANGUARD CAPITAL MANAGEMENT LLC | 37.7M | $3.0B | 6.50% | new | | VANGUARD PORTFOLIO MANAGEMENT LLC | 26.4M | $2.1B | 4.55% | new | | STATE STREET CORP | 26.3M | $2.1B | 4.53% | +1.2% | | WELLINGTON MANAGEMENT GROUP LLP | 22.0M | $1.8B | 3.79% | +1.0% | | JPMORGAN CHASE & CO | 21.7M | $1.7B | 3.74% | −16.4% | | Bank of New York Mellon Corp | 16.7M | $1.3B | 2.88% | −4.3% | | FMR LLC | 14.5M | $1.2B | 2.50% | −12.5% |
Δ vs 2025-Q4ⓘ Latest reported quarterslast report 2026-07-23 | Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|
| 2026-06-30 | 2026-07-23 | $0.42 | −25.0% | $1.74B | +13.6% | | 2026-03-31 | 2026-04-23 | $0.66 | +8.2% | $1.65B | +16.7% | | 2025-12-31 | 2026-02-10 | — | — | $1.57B | +13.3% | | 2025-09-30 | 2025-10-30 | $0.50 | −90.3% | $1.55B | +14.7% |
As-reported XBRL · next 2026-10-23 est.ⓘ Segment mixFY2025 (ended Dec 2025) Transcatheter Aortic Valve Replacement 74% · Surgical Heart Valve Therapy 17% · Transcatheter Mitral And Tricuspid Therapies 9% product & service · TAGGED revenueⓘ Basis & disclosures - EOD closes · nothing imputed or averaged · absent “—”
- As-of differs by block · 13F = US long, 45+d lag, LOWER bound
- Not investment advice · no recommendation, price target or solicitation
- EDGAR + foreign registers · marketstack (licensed EOD) · spzco.com/methodology
| 
